EG 427 funding news – Paris-based EG 427 Secures €27 Million in Series B Round Funding

Philippe Chambon, MD, PhD, Chief Executive Officer at EG 427 said, “The successful closing of this Series B financing is a major milestone for EG 427, which brings us the strong support of two major institutional investors, Andera Partners and Bpifrance, participation of the specialist fund, SCI Ventures, and the continuous support of our existing investors. Genetic medicine solutions have the potential to address major medical needs affecting large patient population with chronic diseases. Initially, our focus is on pathologies in neuro-urology. This field is currently underserved and lacks significant recent medical innovations, despite its huge costs to the healthcare systems. This funding allows us to advance our first program focussed on dysfunctions of the bladder, such as neurogenic bladder, through its initial clinical trial. This first human study, currently in progress, will provide a read on safety and possibly early efficacy,”.

The company claims this is the first human study using this type of treatment for sensory neuron-based diseases. The product, EG110A, targets serious bladder issues like neurogenic bladder (NDO) and overactive bladder (OAB), and could be a big improvement over current treatments, offering better patient care and lowering healthcare costs.

Read also - Pixel Photonics funding news – Munster-based DeepTech Startup Pixel Photonics Secures €1 Million in Funding

EG110A is a genetic medicine using a non-replicating HSV-1 vector. It is designed to block the signals from bladder sensory neurons that cause muscle overactivity while keeping bladder function intact. NDO is a common bladder problem caused by spinal cord injury (SCI) and neurodegenerative diseases like multiple sclerosis or Parkinson’s disease.

The company’s HERMES platform delivers precise neurotherapeutic treatments for common diseases affecting both the peripheral and central nervous systems.

Its vectors can target specific areas and deliver genes to certain groups of neurons by using advanced control methods. With proven safety in clinical trials and the possibility for repeated doses, the large capacity of the nrHSV-1 vectors allows for flexible DNA delivery, making genetic medicine more effective.

Benoît Barteau, Investment Director at Bpifrance – InnoBio funds said, “As a world leader in developing non-replicative HSV vectors in neurology, EG 427 has the potential to significantly advance the applications of genetic medicine through highly targeted delivery and local administration. In addition, EG 427’s platform could enable repeated dosing and more affordable production costs compared to AAV based vectors. If successful, this approach could offer a better and longer-term therapeutic solution for patients who suffer from chronic neurological diseases,”.

The funds from this round will be used to develop EG 427’s main genetic medicine, EG110A, to treat neurogenic detrusor overactivity (NDO) in spinal cord injury (SCI) patients. This study in the U.S. could lead to more research into other important, yet neglected, neuro-urology diseases that affect millions.

The financing will also help EG 427 expand its work on new treatments using its HERMES technology. This technology can treat specific diseases, providing long-lasting results at a low cost, benefiting both healthcare systems and patients.

Raphaël Wisniewski, Partner at Andera Partners said, “EG 427’s technology has the potential to significantly disrupt current treatment paradigms. The lead programme EG110A could significantly improve treatment options for a range of underserved neuro-urology indications. We are thrilled to have co-led this financing round to advance EG110A in the clinic and EG 427’s broader genetic medicine pipeline,”.

About EG 427

EG 427 was founded in 2019 by Philippe Chambon, Alberto Epstein, François Giuliano, Pierre Denys, and Charles Joussain. The company is working on a new technology using non-replicating HSV-1 (Herpes Simplex Virus type 1) vectors in neurology. Their unique platform delivers precise and lasting treatments to target common neurological diseases.